89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. - 89Zr-Bevacizumab PET/CT imaging in NF2 patients

eiden University Medical Center0 个研究点目标入组 15 人开始时间: 2020年3月3日最近更新: 2024年4月8日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•-Patients aged 18 years or older
•-Confirmed diagnosis of NF2 by revised Manchester criteria (appendix C)
•-Provided written informed consent
•-Patients must have measurable disease, defined as at least one VS > 0.4 ml (on volumetric analysis) that can be accurately measured by contrast-enhanced T1-weighted cranial MRI scan.
•-Eligible and planned for bevacizumab treatment
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•-Patients with a contra-indication for PET and MRI, such as pregnancy and metal elements.
•-Patients with a known allergy to substances used in this study

发起方

eiden University Medical Center